Moreover, a recent study has determined that FGFR4 drives phenotypic switching of luminal A breast cancers to a HER2-enriched gene expression phenotype, and that a FGFR4-induced expression signature is positively associated with poor outcome and site-selective metastasis [29]. This evidence concerns the gene FGFR4 and breast carcinoma.